<DOC>
	<DOCNO>NCT02992015</DOCNO>
	<brief_summary>Diffuse Intrinsic Pontine Glioma ( DIPG ) aggressive childhood brain tumor , despite many past clinical trial , never show respond chemotherapy . Radiation therapy ( RT ) effective extend life curative ; median overall survival 11 month . It still unclear hundred clinical trial involve chemotherapy DIPG fail demonstrate activity tumor . Given many agent try clinical trial cross blood brain barrier ( BBB ) , possible factor specific DIPG location prevent adequate drug penetration . Gemcitabine select study strong evidence DIPG cell line inhibition vitro good BBB penetration . Furthermore , pediatric dose toxicity establish prior study child relapse solid tumor leukemia . The primary aim study determine presence gemcitabine childhood DIPG tissue systemic treatment drug . The secondary aim quantify intratumoral gemcitabine concentration systemic treatment . Participants study give one time IV dose gemcitabine prior standard care surgery . During surgery biopsy obtain clinical research purpose along blood sample . Because patient undergo biopsy part standard care therapy Children 's Hospital Colorado , optimal time obtain tumor biopsy study . The biopsy serve see study drug penetrate tumor . Patients enter follow-up period 30 day post surgery .</brief_summary>
	<brief_title>Gemcitabine Newly-Diagnosed Diffuse Intrinsic Pontine Glioma</brief_title>
	<detailed_description />
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<criteria>1 . Age great equal 3 year less 18 year time enrollment 2 . Patients must meet following : Clinical finding consistent presume new diagnosis DIPG Brain MRI finding consistent new diagnosis DIPG opinion treat pediatric neurooncologist neurosurgeon 3 . Organ Function Requirements Adequate bone marrow function define : Platelet count ≥100,000/µl ( platelet transfusion 3 day ) Hemoglobin &gt; 8 g/dl absolute neutrophil count ( ANC ) ≥1,000/µl Adequate coagulation define : Prothrombin time ( PT ) activate partial thromboplastin time ( aPTT ) ≤ upper limit normal ( ULN ) age . Adequate renal function define : Creatinine clearane radioisotope GFR &gt; 70 ml/min/1.73 m2 Maximum serum creatinine ( mg/dL ) base age/gender follow : Male 3 &lt; 6 yr : 0.8 mg/dL Female 3 &lt; 6 yr : 0.8 mg/dL Male 6 &lt; 10 yr : 1.0 mg/dL Female 6 &lt; 10 yr : 1.0 mg/dL Male 10 &lt; 13 yr : 1.2 mg/dL Female 10 &lt; 13 yr : 1.2 mg/dL Male 13 &lt; 16 yr : 1.5 mg/dL Female 13 &lt; 16 yr : 1.4 mg/dL Male 16 &lt; 18 yr : 1.7 mg/dL Female 16 &lt; 18 yr : 1.4 mg/dL The threshold creatinine value Table derive Schwartz formula estimate GFR ( Schwartz et al . J. Peds , 106:522 , 1985 ) utilize child length stature data publish CDC . Adequate liver function define : Total bilirubin &lt; 3x ULN age SGOT ( AST ) SGPT ( ALT ) &lt; 2.5x ULN age 4 . Patients must meet one follow performance score : ECOG performance status score 0 , 1 , 2 ; Karnofsky score ≥ 60 patient &gt; 16 year age ; Lansky score ≥ 60 patient ≤ 16 year age 5 . Pontine tumor biopsy plan clinical care patient independent study participation treat pediatric neurosurgeon neurooncologist . 6 . Informed consent assent obtain appropriate . 1 . Pregnant breastfeeding patient due teratogenic effect see animal/human study . 2 . Patients receive tumordirected therapy prior biopsy . Concurrent treatment corticosteroid allow . 3 . Patients intratumoral hemorrhage large 0.5 cm preoperative imaging . 4 . Patients personal family history bleeding disorder . 5 . Patients uncontrolled intercurrent illness include , limited ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement .</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>